15, breast cancer patients with estimated risk of FN > 20% who were considered fit to receive 3-weekly polychemotherapy were randomized to primary granulocyte colony-stimulating factor (G-CSF) prophylaxis during the first two cycles (experimental arm) or to G-CSF prophylaxis during all cycles (standard arm). The gene discussed is CSF3; the disease is breast carcinoma.